Q3 EPS Forecast for Entrada Therapeutics Reduced by Analyst

Entrada Therapeutics, Inc. (NASDAQ:TRDA) – Stock analysts at William Blair decreased their Q3 2025 earnings per share estimates for shares of Entrada Therapeutics in a note issued to investors on Wednesday, August 6th. William Blair analyst M. Minter now expects that the company will post earnings per share of ($0.88) for the quarter, down from their prior estimate of ($0.76). The consensus estimate for Entrada Therapeutics’ current full-year earnings is $1.12 per share. William Blair also issued estimates for Entrada Therapeutics’ Q4 2025 earnings at ($0.78) EPS, FY2025 earnings at ($3.13) EPS, Q1 2026 earnings at ($0.80) EPS, Q2 2026 earnings at ($0.83) EPS, Q3 2026 earnings at ($0.88) EPS, Q4 2026 earnings at ($0.93) EPS, FY2026 earnings at ($3.44) EPS and FY2027 earnings at ($3.83) EPS.

Entrada Therapeutics (NASDAQ:TRDA) last announced its quarterly earnings data on Wednesday, August 6th. The company reported ($1.04) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.18). The firm had revenue of $1.98 million for the quarter, compared to analysts’ expectations of $8.17 million. Entrada Therapeutics had a negative net margin of 92.30% and a negative return on equity of 17.81%.

A number of other equities research analysts have also recently issued reports on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price objective on shares of Entrada Therapeutics in a research note on Tuesday, May 20th. Wall Street Zen cut shares of Entrada Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday. One investment analyst has rated the stock with a sell rating, three have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $25.67.

Entrada Therapeutics Trading Down 2.1%

Shares of NASDAQ TRDA opened at $5.19 on Monday. Entrada Therapeutics has a 1-year low of $4.98 and a 1-year high of $21.79. The stock has a market cap of $197.43 million, a price-to-earnings ratio of -2.92 and a beta of -0.12. The stock’s 50-day moving average is $6.90 and its 200 day moving average is $8.96.

Institutional Trading of Entrada Therapeutics

Institutional investors have recently made changes to their positions in the stock. Public Employees Retirement System of Ohio boosted its holdings in shares of Entrada Therapeutics by 6.2% in the fourth quarter. Public Employees Retirement System of Ohio now owns 17,259 shares of the company’s stock worth $298,000 after buying an additional 1,000 shares during the last quarter. ExodusPoint Capital Management LP boosted its holdings in shares of Entrada Therapeutics by 7.3% in the fourth quarter. ExodusPoint Capital Management LP now owns 16,453 shares of the company’s stock worth $284,000 after buying an additional 1,113 shares during the last quarter. WCG Wealth Advisors LLC boosted its holdings in shares of Entrada Therapeutics by 6.2% in the fourth quarter. WCG Wealth Advisors LLC now owns 24,030 shares of the company’s stock worth $415,000 after buying an additional 1,406 shares during the last quarter. Martingale Asset Management L P boosted its holdings in shares of Entrada Therapeutics by 4.0% in the first quarter. Martingale Asset Management L P now owns 40,163 shares of the company’s stock worth $363,000 after buying an additional 1,540 shares during the last quarter. Finally, Bank of America Corp DE boosted its holdings in shares of Entrada Therapeutics by 4.9% in the fourth quarter. Bank of America Corp DE now owns 35,721 shares of the company’s stock worth $618,000 after buying an additional 1,660 shares during the last quarter. Hedge funds and other institutional investors own 86.39% of the company’s stock.

Insider Buying and Selling at Entrada Therapeutics

In related news, major shareholder Ventures V. L.P. 5Am sold 55,735 shares of the stock in a transaction dated Friday, June 27th. The shares were sold at an average price of $6.91, for a total value of $385,128.85. Following the completion of the transaction, the insider directly owned 3,220,287 shares in the company, valued at $22,252,183.17. This trade represents a 1.70% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Kush Parmar sold 75,000 shares of the stock in a transaction dated Friday, June 27th. The stock was sold at an average price of $6.91, for a total transaction of $518,250.00. Following the completion of the transaction, the director owned 1,113,092 shares of the company’s stock, valued at approximately $7,691,465.72. The trade was a 6.31% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 254,000 shares of company stock valued at $1,782,000 over the last 90 days. Company insiders own 7.59% of the company’s stock.

About Entrada Therapeutics

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.